Our Board

Stuart is a world-renowned biophysicist. A foreign associate of the French Academy of Science, his academic curriculum includes professorships at Cornell University (NY, USA), University of Geneva (Switzerland), ENS (Paris, France) and the Collège de France. Stuart also has start-up experience as co-founder of a publicly listed biotech company.

Philippe, a partner at Seventure Partners, is in charge of life siences investments for the Quadrivium I fund. He started his career as a Project Manager and Director of Business Development Europe in the Rhodia group and later founded a market and business intelligence company, CBDMT – Market & Business Intelligence, which he managed for 10 years prior to joining Seventure.

Jean-Pascal Viola is the Senior Vice-President, Head of the Molecular Diagnostics Business Area at QIAGEN, in addition to his role as leader of corporate business development and intellectual property and litigation. He joined Qiagen in 2005 and has held various roles in Singapore, the US, and Germany. He played a leading role in the acquisitions of Cellestis, Stat-Dx, NeuMoDx, and the assets of Formulatrix related to digital PCR.

Nathalie is Associate Vice-President, head of the Program Management Office of the Diagnostics and Genomics Group at Agilent Technologies. Nathalie is passionate about improving human lives. After 5 years as a researcher in microfluidics, including a PhD on single cell transcriptome analysis and a patent on monodisperse emulsions, Nathalie joined Agilent Technologies. With 15 years of WW commercial and operational experience, in roles ranging from field marketing, sales, operations and business development, Nathalie brings an outstanding track record of building teams and driving transformation in highly complex, cross-cultural environments.

Cheryl is part of M Ventures, the corporate Venture Capital arm of Merck. She joined M Ventures in May 2016 and is an Investment Director in the Biotechnology team. Cheryl received her BSc. Hons. in Biology from the University of Utrecht, a MSc in Biotechnology from the University of Wageningen and a PhD in Oncology from the University of Amsterdam. Before joining M Ventures she had a successful academic career publishing in top-tier academic journals, including Nature. Cheryl is based in Amsterdam.

Frank is Senior Investment Manager at High-Tech Gründerfonds. He brings significant experience in biotechnology, as a scientist and founder of OncoMab GmbH, a spin-off of the University of Würzburg's Institute of Pathology. This expert in tumour-reactive antibodies focuses on the development of biologicals from the manufacturing phase to the clinical-trial stage.

Louis Geslin joined Financière Arbevel in 2016 as an equity analyst in the healthcare sector. Since 2018, he has co-managed the unlisted Arbevel Life Sciences Crossover I fund. Louis began his career in the hospital sector (Hôpital Timone, Institut Paoli-Calmettes) and then in venture capital funds (Seventure Partners, Advent Life Sciences, Bpifrance). Louis is a Board member at NG Biotech, Imactis (sold to GE Healthcare in December 2022), TransCure BioServices and Germitec and a Board observer at UroMems. Louis holds a pharmacy degree and is a graduate of the ESSEC Grande Ecole program.

Christian joined M Ventures in August 2019 and is a Principal in the Biotechnology team. Before joining M Ventures he worked at Merck as Healthcare and Life Science focused inhouse consultant. Prior, he worked as an ext. consultant focused on Biopharma/tech and Tech for more than a decade. Christian holds an MBA from Mannheim Business School, Germany and a Diploma in Computer Science and Business Administration (Business Informatics) from Cooperative State University Karlsruhe, Germany. Christian is based in Darmstadt.